DNTH vs V · rev $6.2M vs P/E 33, rev $40.00B
Dianthus Therapeutics Inc. (DNTH) versus Visa Inc. Class A (V) — a side-by-side from cached financials, not a winner call.
Dianthus Therapeutics Inc. (DNTH) is a biotechnology company listed on US.
Visa Inc. Class A (V) is a credit services company listed on US. It is led by Ryan McInerney.
Latest reported DNTH revenue for 2024-12-31 was $6.2M. Net income was -$85.0M. Revenue was up 120.6% from 2023-12-31 to 2024-12-31. DNTH currently screens at market cap $4.40B.
Latest reported V revenue for 2025-09-30 was $40.00B. Net income was $20.06B. V currently screens at market cap $659.78B and trailing P/E 33.5.
DNTH currently screens at market cap $4.40B. V currently screens at market cap $659.78B and trailing P/E 33.5.
Not investment advice. Open the DNTH and V stock pages for the full models.
Not investment advice.